Thomas Mizell, MD
Internal Medicine · Decatur, GANPI 1205829561
Payments from drug & device makers
Across 147 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$370
- Amgen$254
- AbbVie$251
- Lilly USA, LLC$248
- Inspire Medical Systems, Inc.$211
- GSK$199
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,78899%
- Gifts$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $370 |
| Amgen | 16 | $254 |
| AbbVie | 14 | $251 |
| Lilly USA, LLC | 12 | $248 |
| Inspire Medical Systems, Inc. | 4 | $211 |
| GSK | 11 | $199 |
| Astellas Pharma US Inc | 8 | $170 |
| AstraZeneca | 7 | $109 |
| Pfizer | 6 | $106 |
| Exact Sciences | 4 | $98 |
| Johnson & Johnson | 6 | $93 |
| Merck | 6 | $80 |
| Sanofi Pasteur Inc. | 4 | $78 |
| Paratek Pharmaceuticals, Inc. | 3 | $66 |
| Bayer | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Dexcom, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Boston Scientific | 1 | $41 |
| Boehringer Ingelheim | 2 | $33 |
| Almatica Pharma LLC | 1 | $32 |
| Echosens North America, Inc. | 2 | $28 |
| Linus Health, Inc. | 2 | $28 |
| Optinose US, Inc. | 1 | $25 |
| Welch Allyn | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Emmaus Medical, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Abbott | 1 | $15 |
How this compares
$2,811 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $124,769 |
| JardianceEmpagliflozin | 58 | $77,147 |
| TrulicityDulaglutide | 30 | $41,364 |
| EliquisApixaban | 33 | $31,645 |
| MyrbetriqMirabegron | 37 | $26,323 |
| RybelsusSemaglutide | 11 | $23,377 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $15,915 |
| LinzessLinaclotide | 16 | $13,952 |
| TradjentaLinagliptin | 13 | $12,159 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $11,127 |
| Repatha SureclickEvolocumab | 13 | $10,587 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $8,319 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,659 |
| Levothyroxine Sodium | 380 | $4,305 |
| Atorvastatin Calcium | 372 | $3,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $370 | $148,146103 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $33 | $105,22188 claims |
| Lilly USA, LLCTrulicity | $248 | $41,36430 claims |
| PfizerEliquis, Paxlovid | $106 | $33,07552 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $26,32337 claims |
| AbbVieLinzess, Namzaric, Synthroid | $251 | $24,05558 claims |
| MerckJanumet | $80 | $11,12711 claims |
| GSKAnoro Ellipta, Arnuity Ellipta | $199 | $8,97226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Decatur
- Ahmad JingoDecatur$867K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.